Laurentian Bank of Canada lowered shares of Synthetic Biologics Inc (NYSEMKT:SYN) from a buy rating to a speculative buy rating in a research report released on Friday, reports.

SYN has been the subject of a number of other research reports. Zacks Investment Research lowered Synthetic Biologics from a hold rating to a sell rating in a research note on Tuesday, November 1st. Griffin Securities set a $5.80 price objective on Synthetic Biologics and gave the company a buy rating in a research note on Wednesday, August 31st. BTIG Research began coverage on Synthetic Biologics in a research note on Thursday, August 25th. They set a buy rating and a $5.00 price objective for the company. Finally, FBR & Co restated a buy rating on shares of Synthetic Biologics in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. Synthetic Biologics has a consensus rating of Buy and a consensus target price of $5.41.

Shares of Synthetic Biologics (NYSEMKT:SYN) opened at 0.7968 on Friday. The company’s market cap is $73.44 million. The stock has a 50 day moving average of $1.30 and a 200 day moving average of $1.67. Synthetic Biologics has a 1-year low of $0.77 and a 1-year high of $3.00.

Synthetic Biologics (NYSEMKT:SYN) last issued its earnings results on Tuesday, November 1st. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.01. Analysts predict that Synthetic Biologics will post ($0.35) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by Financial Market News and is the propert of of Financial Market News. If you are accessing this news story on another site, it was stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this news story can be read at

An institutional investor recently raised its position in Synthetic Biologics stock. UBS Group AG boosted its position in Synthetic Biologics Inc (NYSEMKT:SYN) by 378.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 288,367 shares of the company’s stock after buying an additional 228,037 shares during the period. UBS Group AG owned approximately 0.32% of Synthetic Biologics worth $680,000 as of its most recent SEC filing.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Stock Target Prices

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with's FREE daily email newsletter.